Protagonist Therapeutics, Inc.

NASDAQ (USD): Protagonist Therapeutics, Inc. (PTGX)

Last Price

44.83

Today's Change

-0.70 (1.53%)

Day's Change

44.31 - 46.51

Trading Volume

668,923

Overview

Market Cap

2 Billion

Shares Outstanding

59 Million

Avg Volume

678,131

Avg Price (50 Days)

45.24

Avg Price (200 Days)

35.98

PE Ratio

16.36

EPS

2.74

Earnings Announcement

25-Feb-2025

Previous Close

45.53

Open

45.20

Day's Range

44.31 - 46.515

Year Range

17.13 - 48.89

Trading Volume

688,183

Price Change Highlight

1 Day Change

-1.54%

5 Day Change

9.39%

1 Month Change

-5.14%

3 Month Change

7.76%

6 Month Change

47.42%

Ytd Change

91.42%

1 Year Change

157.35%

3 Year Change

34.79%

5 Year Change

474.74%

10 Year Change

283.16%

Max Change

283.16%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment